Shu-Ching Chen1, Yeur-Hur Lai2, Bing-Shen Huang3, Chien-Yu Lin3, Kang-Hsing Fan3, Joseph Tung-Chien Chang3. 1. Department of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan; Head and Neck Oncology Group, Chang Gung Medical Foundation, Chang Gung Memorial Hospital at LinKou, Taoyuan, Taiwan. Electronic address: shuching@gw.cgust.edu.tw. 2. School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan. 3. Department of Radiation Oncology, Chang Gung Medical Foundation, Chang Gung Memorial Hospital at LinKou and Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Head and Neck Oncology Group, Chang Gung Medical Foundation, Chang Gung Memorial Hospital at LinKou, Taoyuan, Taiwan.
Abstract
PURPOSE: Radiation-induced oral mucositis (OM) is the most debilitating side effect of radiation treatment in oral cavity cancer. The purpose of the study was to investigate change of prevalence of severe OM, OM-related symptoms, and predictors in oral cavity cancer patients during active treatment. METHODS AND SAMPLE: Longitudinal study design with repeated measures was used. Patients with oral cavity cancer were recruited from a head and neck outpatient radiation department at a major medical center in Taiwan. Patients' OM-related symptoms were measured at three time points. Patients' oral mucosa was assessed at nine time points. Generalized estimating equations (GEE) were used to analyze the predictive factors of prevalence of severe OM and OM-related symptoms. RESULTS: Patients reported highest prevalence of severe OM at T5 (5 weeks after beginning RT) and T6 (6 weeks after beginning radiation therapy, RT), with the combined chemotherapy and RT (CCRT) patients reporting a higher prevalence than those receiving RT alone. The peak of OM-related symptoms was at T8 (8 week after beginning RT), with primary symptoms of mouth pain, mouth dryness, eating difficulties, swallowing difficulties, and taste change. Patients with CCRT, a higher cumulative radiation dose, smoking, and lower body mass index (BMI) were at high risk to develop severe OM. OM-related symptoms were predicted by type of treatment, cumulative radiation dose, and smoking. CONCLUSIONS: Patients with oral cavity cancer suffer from OM and OM-related symptoms during aggressive RT or CCRT. Patient-specific oral care and emotional support are needed to relieve distressful OM-related symptoms during active treatment.
PURPOSE: Radiation-induced oral mucositis (OM) is the most debilitating side effect of radiation treatment in oral cavity cancer. The purpose of the study was to investigate change of prevalence of severe OM, OM-related symptoms, and predictors in oral cavity cancerpatients during active treatment. METHODS AND SAMPLE: Longitudinal study design with repeated measures was used. Patients with oral cavity cancer were recruited from a head and neck outpatient radiation department at a major medical center in Taiwan. Patients' OM-related symptoms were measured at three time points. Patients' oral mucosa was assessed at nine time points. Generalized estimating equations (GEE) were used to analyze the predictive factors of prevalence of severe OM and OM-related symptoms. RESULTS:Patients reported highest prevalence of severe OM at T5 (5 weeks after beginning RT) and T6 (6 weeks after beginning radiation therapy, RT), with the combined chemotherapy and RT (CCRT) patients reporting a higher prevalence than those receiving RT alone. The peak of OM-related symptoms was at T8 (8 week after beginning RT), with primary symptoms of mouth pain, mouth dryness, eating difficulties, swallowing difficulties, and taste change. Patients with CCRT, a higher cumulative radiation dose, smoking, and lower body mass index (BMI) were at high risk to develop severe OM. OM-related symptoms were predicted by type of treatment, cumulative radiation dose, and smoking. CONCLUSIONS:Patients with oral cavity cancer suffer from OM and OM-related symptoms during aggressive RT or CCRT. Patient-specific oral care and emotional support are needed to relieve distressful OM-related symptoms during active treatment.
Authors: Heidi Mason; Mary Beth DeRubeis; Nancy Burke; Melissa Shannon; Danielle Karsies; Gregory Wolf; Avi Eisbruch; Francis Worden Journal: World J Clin Oncol Date: 2016-04-10
Authors: L Hu; Y Wang; A P Cotrim; Z Zhu; R Gao; C Zheng; C M Goldsmith; L Jin; C Zhang; J B Mitchell; B J Baum; S Wang Journal: Oral Dis Date: 2017-04-27 Impact factor: 3.511
Authors: Hiram A Gay; Jung Hun Oh; Aditya P Apte; Mackenzie D Daly; Douglas R Adkins; Jason Rich; Peter J Oppelt; Pawel T Dyk; Daniel F Mullen; Laura Eschen; Re-I Chin; Brian Nussenbaum; Bruce H Haughey; Wade L Thorstad; Joseph O Deasy Journal: Clin Transl Radiat Oncol Date: 2018-09-04
Authors: Stine Mogensen; Charlotte Treldal; Claus A Kristensen; Jens Bentzen; Louise Lawson-Smith; Janne Petersen; Ove Andersen Journal: Pain Rep Date: 2017-08-23